ViiV Healthcare's Lotivibart Shows Strong Viral Suppression in Long-Acting HIV Regimen
Event summary
- ViiV Healthcare's phase IIb EMBRACE study shows lotivibart (N6LS) maintains viral suppression in 94% of participants via IV and 82% via SC when combined with monthly CAB LA.
- 12-month data presented at CROI 2026 reinforces lotivibart's potential for ultra long-acting HIV treatment, with plans to evaluate twice-yearly IV dosing.
- Lotivibart was generally well tolerated, with higher grade infusion-site reactions reported in 16% of SC group participants compared to none in the IV group.
- ViiV Healthcare aims to progress the study based on positive interim results, building on six-month data presented at CROI 2025.
The big picture
ViiV Healthcare's positive 12-month data for lotivibart underscores the growing trend towards long-acting HIV treatments, which offer greater convenience and potentially better adherence for patients. The company's focus on ultra long-acting regimens aligns with broader industry efforts to innovate in HIV treatment, aiming to reduce the burden of frequent dosing. The strategic shift towards twice-yearly dosing could significantly impact the competitive landscape and patient outcomes.
What we're watching
- Regulatory Approval
- The pace at which ViiV Healthcare can secure regulatory approval for lotivibart's ultra long-acting dosing regimen will determine its market entry timing.
- Market Adoption
- Whether the combination of lotivibart and CAB LA can gain significant market share against existing HIV treatment options.
- Competitive Dynamics
- How competitors in the HIV treatment space, such as Gilead Sciences, respond to ViiV Healthcare's long-acting regimen advancements.
Related topics